High-potency benzodiazepines: recent clinical results.

Area of Science:

• Psychiatry
• Pharmacology

Background:

• High-potency benzodiazepines like alprazolam, clonazepam, and lorazepam are established treatments for anxiety disorders.
• Existing efficacy and safety data for these anxiolytics are several years old.

Purpose of the Study:

• To review updated information on clonazepam and alprazolam, focusing on new formulations.
• To assess the clinical utility of new formulations in managing anxiety disorders, particularly panic disorder.

Main Methods:

• Review of bioequivalence studies for new clonazepam formulation (lyophilized wafer).
• Examination of U.S. multicenter trials and recent publications on clonazepam's efficacy.
• Literature review of a new extended-release alprazolam formulation for panic disorder.

Main Results:

• Clonazepam's new lyophilized wafer formulation enhances ease of administration without altering pharmacology.
• Strong evidence supports clonazepam's use in panic disorder, with additional data on augmentation therapy and depression recurrence prevention.
• Extended-release alprazolam allows once-daily dosing, maintaining therapeutic concentrations and potentially reducing dose-fluctuation effects.

Conclusions:

• New formulations of clonazepam and alprazolam enhance treatment convenience and potentially improve therapeutic outcomes.
• These updated benzodiazepine formulations represent significant advancements in managing anxiety and related conditions.